Commerzbank Ag Reiterates “€58.00” Price Target for STADA Arzneimittel AG (SAZ)
STADA Arzneimittel AG (ETR:SAZ) has been given a €58.00 ($68.24) price objective by analysts at Commerzbank Ag in a research note issued to investors on Wednesday. The firm presently has a “sell” rating on the stock.
Several other equities analysts have also commented on the company. Independent Research GmbH set a €66.25 ($77.94) price target on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research note on Wednesday, August 9th. S&P Global set a €66.25 ($77.94) price target on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research note on Thursday, August 3rd. Kepler Capital Markets set a €66.00 ($77.65) price target on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research note on Tuesday, July 11th. Finally, Warburg Research set a €60.00 ($70.59) target price on STADA Arzneimittel AG and gave the stock a “neutral” rating in a research report on Wednesday, July 5th. Three equities research analysts have rated the stock with a sell rating and two have given a hold rating to the stock. The company presently has a consensus rating of “Sell” and a consensus price target of €65.30 ($76.82).
STADA Arzneimittel AG (ETR SAZ) traded up 4.549% on Wednesday, reaching €75.275. The company had a trading volume of 11,514 shares. The company has a market capitalization of €4.69 billion and a PE ratio of 49.752. STADA Arzneimittel AG has a 52-week low of €41.40 and a 52-week high of €75.28. The company’s 50-day moving average is €65.34 and its 200-day moving average is €61.72.
About STADA Arzneimittel AG
Stada Arzneimittel AG is a Germany-based holding company active in the pharmaceutical sector and healthcare market. The Company develops and markets products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are Generics and Branded Products. The Generics segment comprises low-priced and active-ingredient products.
Receive News & Ratings for STADA Arzneimittel AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel AG and related companies with MarketBeat.com's FREE daily email newsletter.